Group 1 - The China Securities Regulatory Commission has issued a notice regarding Hangzhou Deshi Biotechnology Co., Ltd.'s overseas issuance and the "full circulation" of unlisted shares in China, with plans to issue up to 31.04 million overseas listed ordinary shares on the Hong Kong Stock Exchange [1] - A total of 27 shareholders intend to convert a combined 80.88 million unlisted shares into overseas listed shares for circulation on the Hong Kong Stock Exchange [1][4][5] Group 2 - Deshi Biotechnology focuses on the medical imaging AI industry, with its proprietary iMedImageTM model supporting 19 types of medical imaging modalities and covering over 90% of clinical medical imaging scenarios [3] - The iMedImageTM model is recognized as the world's largest general-purpose medical imaging base model and has been successfully commercialized, being the first commercialized cross-modal medical imaging base model [3]

Group 1 - The core point of the news is that Hangzhou Deshi Biotechnology Co., Ltd. plans to issue up to 31.04 million overseas listed ordinary shares and convert 80.88 million domestic unlisted shares into overseas listed shares for trading on the Hong Kong Stock Exchange [1][3]. Group 2 - Deshi Biotechnology focuses on the medical imaging AI industry, with its proprietary iMedImageTM model supporting 19 types of medical imaging modalities and covering over 90% of clinical medical imaging scenarios [3]. - The iMedImageTM model is recognized as the world's largest general-purpose medical imaging base model and the first commercialized cross-modal medical imaging base model [3]. Group 3 - A total of 27 shareholders are involved in the conversion of shares, with the largest shareholder, Song Ning, converting 24,293,507 shares [4][5]. - The total number of shares being converted by all shareholders amounts to 80,880,000 [5].

Group 1 - The core viewpoint of the news is that Hangzhou Deshi Biotechnology Co., Ltd. submitted its Hong Kong IPO prospectus on June 29, which became invalid after six months on December 29, with Huatai International serving as the sole sponsor [1] - The prospectus indicates that Deshi Biotechnology's self-developed iMedImageTM is the largest general-purpose medical imaging base model in terms of parameter scale globally, which has been successfully commercialized [2] - iMedImageTM is recognized as the world's first commercialized cross-modal medical imaging base model [2]

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 17 companies, including Deshi Biotech, regarding their overseas listing applications [1][2] - Deshi Biotech submitted its listing application to the Hong Kong Stock Exchange on June 29, 2025, with Huatai International as the sole sponsor [1] - The CSRC has requested Deshi Biotech to clarify its business scope and whether it involves any foreign investment restrictions, particularly in areas like human stem cells and gene diagnosis and treatment [1][2] Group 2 - Deshi Biotech's proprietary iMedImageTM is recognized as the world's largest general medical imaging base model and has been commercialized successfully [2] - The iMedImageTM model supports 19 types of medical imaging modalities and covers over 90% of clinical medical imaging scenarios, enhancing diagnostic efficiency and addressing uneven distribution of medical resources [2] - The company focuses on AI solutions for medical imaging, which significantly reduce R&D costs and time to market, providing scalable innovative pathways for smart healthcare [2]